---
granola_id: 8d646d54-fe65-46e0-bea4-ea83596b27d7
title: "Taylor Chartier and Virtue"
type: note
created: 2025-10-10T17:16:13.130Z
updated: 2025-10-10T17:30:30.964Z
attendees:
  - taylor@modicusprime.com
  - sd@virtuevc.com
---
### mPVision Technology Platform

- Patent-protected imaging solution tailored for biologics
- Pharma companies own their AI models and data
	- Upload imaging data to mPVision for training
	- Domain experts label and train AI on proprietary information
	- Deploy fully in-house for security
- Integrates with pharma imaging devices
	- Microflow imaging devices
	- Microscopes
	- Image flow cytometers
- Configured specifically for unique biologic molecules vs off-the-shelf solutions

### Product Portfolio

- mPText: Language model for quality processes
	- Assists biologics companies with deviation report writing
	- Performs root cause analysis for manufacturing failures
	- Reviews quality management systems to identify relevant SOPs
- Pipeline products (mPSignal/mPSeries)
	- Manufacturing execution systems integration
	- Temperature sensors and process monitoring
	- Standalone AI solutions for less AI-mature pharma companies
- Core compliance platform
	- Master product that enables AI deployment
	- Can operate standalone without AI plugins
	- Required for regulated manufacturing compliance

### Commercial Traction

- Current customers:
	- Takeda Pharmaceuticals
		- MSA with tiered ramp-up structure starting at $115k
		- $345k top tier triggers 5-year license deal
		- $2M total contract value potential
		- Focus on computer vision in manufacturing
	- SK Pharma TECO (CDMO)
		- 3-month pilot converting to $390k annual license
		- Using mPText technology
		- Pilot ends by Thanksgiving, expected to close by year-end
- Scoping phase prospects: Novo Nordisk (most advanced), Eli Lilly (just added)
	- Pipeline represents ~$4M potential ARR
- Pricing: $390k annual license + $50k one-time installation fee

### Fundraising Strategy

- Raising $3.5-5M seed round
- Previous round: $2M with Silverton Partners (lead) + $500k from insiders
- Use of funds:
	- Build customer success team
	- Expand sales force
	- Support large logo conversions
- Target: $5M ARR by end of 2027 to enable Series A
- Land-and-expand strategy with compliance as entry wedge

### Next Steps

- Taylor to send pitch deck
- Virtue team will discuss in Monday morning meeting
- Follow-up with next steps after internal review

Chat with meeting transcript: https://notes.granola.ai/d/8d646d54-fe65-46e0-bea4-ea83596b27d7
